LifeMD Inc Preferred Series A
$ 23.74
-0.75%
20 Apr - close price
- Market Cap N/A
- Current Price $ 23.74
- High / Low $ 23.95 / 23.74
- Stock P/E N/A
- Book Value 0.50
- EPS -2.26
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.07 %
- ROE -1.31 %
- 52 Week High 24.00
- 52 Week Low 17.64
About
LifeMD, Inc. is a direct-to-patient telehealth company that connects consumers with healthcare professionals for care in a variety of indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company is headquartered in New York, New York.
Analyst Target Price
N/A
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | Sep 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-17 | 2025-08-05 | 2025-05-06 | 2025-03-11 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 |
| Reported EPS | -0.1 | -0.06 | 0.01 | -0.02 | -0.54 | -0.6402 | -0.4742 | -2.5677 | -1.65 | -0.3655 | -0.23 | -0.071 |
| Estimated EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surprise | -0.1 | -0.06 | 0.01 | -0.02 | -0.54 | -0.6402 | -0.4742 | -2.5677 | -1.65 | -0.3655 | -0.23 | -0.071 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Apr 2026 | Jan 2026 | Oct 2025 | Jan 1970 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-04-15 | 2026-01-15 | 2025-10-15 | None | 2025-04-15 | 2025-01-15 | 2024-10-15 | 2024-07-15 | 2024-04-15 | 2024-01-15 |
| Amount | $0.5546875 | $0.5546875 | $0.5546875 | $0.5546875 | $0.5546875 | $0.5546875 | $0.5546875 | $0.5546875 | $0.5546875 | $0.5546875 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LFMDP
2026-04-15 09:09:17
JPMorgan Chase & Co. significantly reduced its stake in LifeMD, Inc. by 85.2% in Q3, selling 351,630 shares but still retaining 60,941 shares valued at approximately $414,000. Despite LifeMD missing its recent quarterly earnings and revenue estimates, analysts maintain a "Moderate Buy" consensus and a target price of $9.14, significantly higher than its current trading price of $3.77. Other institutional investors like MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd., Creative Planning, Legal & General Group Plc, Rhumbline Advisers, and Russell Investments Group Ltd. have either increased or initiated positions in LifeMD.
2026-04-10 17:09:36
LifeMD, Inc. announced it is now offering Eli Lilly and Company’s Foundayo™ (orforglipron), a new once-daily oral GLP-1 treatment for weight management, to eligible patients through its virtual primary care services. This expansion provides a pill alternative to injectable GLP-1 therapies, accessible via LillyDirect, with a starting self-pay price of $149 per month and potential discounts for commercially insured patients. The company emphasizes its commitment to expanding access to high-quality, affordable weight management care with FDA-approved medications.
2026-04-10 12:09:15
LifeMD, Inc. announced it is now offering Eli Lilly and Company's Foundayo™ (orforglipron) through its weight management program. Foundayo is a new once-daily oral GLP-1 treatment for adults with obesity or overweight with related medical problems. This offering positions LifeMD as a provider of advanced weight management solutions.
2026-04-10 12:09:15
LifeMD, Inc. announced it is now offering Eli Lilly and Company’s new GLP-1 pill, Foundayo™ (orforglipron), for weight management to eligible patients. This once-daily oral treatment is available through LifeMD's integration with LillyDirect®, making it accessible at various price points, including a low self-pay option and potential commercial insurance savings. The addition of Foundayo expands LifeMD's comprehensive weight management program to include a new oral alternative to injectable GLP-1 therapies, reinforcing their commitment to accessible, high-quality care.
2026-04-10 12:09:15
LifeMD (Nasdaq: LFMD) has announced the addition of Eli Lilly's new oral GLP-1 pill, Foundayo (orforglipron), to its weight management program. Foundayo, approved by the FDA on April 1, 2026, will be available to eligible patients starting at $149 per month for self-pay, with potential discounts for commercially insured patients and anticipated Medicare coverage by July 2026. This move expands LifeMD's virtual, clinically guided weight management services, offering an oral alternative to injectable GLP-1 therapies.
2026-04-10 12:09:15
LifeMD, Inc. (NASDAQ:LFMD) has announced the addition of Eli Lilly's FDA-approved oral weight loss drug, Foundayo (orforglipron), to its weight management program. This move expands LifeMD's offerings of GLP-1 therapies and positions the company for potential profitability, with analysts forecasting positive earnings per share this year. The drug is available to eligible patients through integration with LillyDirect, with pricing starting at $149 per month for self-pay and potentially as low as $25 per month for those with eligible commercial insurance.
